Search Results

BioForest

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

November 20, 2023

·

6 min read

BioForest

In Recognition of Sepsis Awareness Month, Magnolia Medical Intensifies Efforts to Combat the Clinical and Economic Risks of Sepsis Misdiagnosis

Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® and the ISDD market, is intensifying efforts to combat sepsis misdiagnosis this Sepsis Awareness Month.

September 7, 2023

·

7 min read

Biotech Beach

USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.

August 15, 2023

·

1 min read

Biotech Beach

Delaware Federal Court Issues a Stay Order in Patent Dispute between Magnolia Medical and Kurin, Inc.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provided an update on the ongoing patent infringement case brought against Kurin by Magnolia Medical.

August 10, 2023

·

2 min read

Policy

USPTO Agrees to Kurin’s Request to Review Validity of Magnolia Medical’s ‘483 Patent

Kurin, Inc. announced that the US Patent and Trademark Office has granted Kurin’s Ex Parte request to reexamine the validity of U.S. Patent No. 10,039,483 that is asserted by Magnolia Medical in ongoing patent litigation.

May 3, 2023

·

2 min read

Policy

Magnolia Medical Technologies Files for Permanent Injunction Against Infringing Kurin Lock Products

Magnolia Medical Technologies, Inc. (“Magnolia Medical”) today announced it filed a motion for permanent injunction in the U.S. District Court for the District of Delaware on September 9, 2022, that would prohibit Kurin, Inc. (“Kurin”) from the continued sale of the infringing Kurin Lock products.

September 13, 2022

·

4 min read

Policy

Magnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc.

A jury for the U.S. District Court of Delaware delivered two unanimous verdicts this week in favor of Magnolia Medical Technologies, Inc. (“Magnolia Medical”) in a lawsuit against Kurin, Inc., (“Kurin”) regarding the unlawful use of its innovative Initial Specimen Diversion Device® (ISDD®) technology.

July 29, 2022

·

3 min read

BioForest

Magnolia Medical Expands Steripath® Micro Initial Specimen Diversion Device® (ISDD®) Product Family with New FDA 510(k) Clearance

Magnolia Medical Technologies, Inc., announced today U.S. Food and Drug Administration (FDA) 510(k) clearance of 19 new Steripath® Micro configurations within the company’s ISDD® product portfolio.

April 11, 2023

·

6 min read

BioForest

Magnolia Medical Announces $46 Million Growth Equity Financing

Magnolia Medical Technologies, Inc., today announced a $46 million growth equity financing co-led by RTW Investments, LP (“RTW”) and Sectoral Asset Management with significant participation by new investor Janus Henderson Investors.

February 16, 2022

·

4 min read

BioForest

Magnolia Medical’s Steripath® Initial Specimen Diversion Device® Only Device Clinically Proven to Meet CDC’s New Guidelines to Reduce Blood Culture Contamination

Magnolia Medical Technologies, Inc., commends the Center for Disease Control and Prevention (CDC) for releasing its new evidence-based guidelines, Blood Culture Contamination: An Overview for Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory.

August 23, 2022

·

5 min read